You are here
- Home
- Last 30 days trials
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Disease
- lymphoma
- Drug Name
- AstraZeneca Oncology and Infection Development Drugs
- Generic Name
- Fostamatinib DLBCL
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- IIb
- Start Date
- Jan 18, 1971
- Study Name
- D4302C00001
- ClinicalTrials.gov ID
- NCT01499303
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
